Zobrazeno 1 - 10
of 633
pro vyhledávání: ''
Autor:
Sapna Pradyuman Patel, David S. Hong, Vivek Subbiah, Amanda Johnston, Siqing Fu, John S. Bomalaski, Sarina Anne Piha-Paul, Shuyang Yao, Ahmed Kaseb, Aung Naing, Nai Shi, Filip Janku, Apostolia Maria Tsimberidou, Shannon N. Westin, John Stewart
Publikováno v:
Br J Cancer
Background Arginine depletion interferes with pyrimidine metabolism and DNA damage-repair pathways, and pairing arginine deiminase pegylated with 20,000-molecular-weight polyethylene glycol (ADI-PEG20) with platinum enhances cytotoxicity in vitro and
Autor:
James Larkin, M.D. Michaelson, Corina E. Dutcus, Robert J. Motzer, Yasuhiro Funahashi, Hilary Glen, Hiroki Ikezawa, Chung-Han Lee, Martin H. Voss, Michio Kanekiyo, Yukinori Minoshima, Pallavi Sachdev
Publikováno v:
British Journal of Cancer
Background No biomarkers have been established to predict treatment efficacy in renal cell carcinoma (RCC). In an exploratory retrospective analysis of a Phase 2 study, we constructed composite biomarker scores (CBSs) to predict progression-free surv
Autor:
Jong Mu Sun, Jinseon Yoo, Kyoung Ho Pyo, Byoung Chul Cho, Se-Heon Kim, Sun Ock Yoon, Hye Ryun Kim, Dong Min Jung, Yoon Woo Koh, Eun Chang Choi, Han Na Kang, Hyo Sup Shim, Kyu Ryung Kim, Kwon Young Ju, Tae Min Kim, Han Sang Kim, Soonmyung Paik, Jae Woo Choi, Min Hee Hong, Mi Ran Yun, Myoung Ju Ahn, Jinna Kim
Publikováno v:
British Journal of Cancer
Background Recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) is a common cancer with high recurrence and mortality. Current treatments have low response rates (RRs). Methods Fifty-three patients with R/M SCCHN received
Autor:
Tadamichi Denda, Mitsugu Kochi, Masahiro Takeuchi, Takeshi Suto, Masashi Fujii, Takao Takahashi, Dai Manaka, Hiroaki Tanioka, Masahito Kotaka, Akinori Takagane, Tamotsu Sagawa, Akihito Tsuji, Wataru Ichikawa, Hiroki Hara, Hideto Fujita, Ken Shimada, Yuji Negoro, Yoshihiko Segawa, Toshiki Masuishi, Takanori Watanabe, Masato Nakamura
Publikováno v:
British Journal of Cancer
Background Regorafenib or trifluridine/tipiracil as third-line treatment have limited efficacy in metastatic colorectal cancer (mCRC). Methods This Phase 2 trial evaluated the efficacy and safety of irinotecan plus cetuximab rechallenge as third-line
Autor:
Gabriel Tremblay, Bruno Daniele, Peter R. Galle, Carlos F. Lopez, Katherine Dick, Thomas R. Jeffry Evans, Richard A Hubner, Uwe Siebert, Andrew Briggs
Publikováno v:
British Journal of Cancer
Background In the Phase 3 REFLECT trial in patients with unresectable hepatocellular carcinoma (uHCC), the multitargeted tyrosine kinase inhibitor, lenvatinib, was noninferior to sorafenib in the primary outcome of overall survival. Post-hoc review r
Autor:
Kristopher Attwood, John Wilton, Wiam Bshara, Katy Wang, Renuka Iyer, Medhavi Gupta, Robert R. Bies, Smitha S. Krishnamurthi, Sunyoung S. Lee, Bassam Estfan, Christos Fountzilas
Publikováno v:
Ann Transl Med
BackgroundHepatocellular carcinoma (HCC) is a major cause of cancer-related death. It is a highly vascular tumour with multiple angiogenic factors, most importantly vascular endothelial growth factor (VEGF), involved in HCC progression. Tivozanib is
Autor:
Dolgormaa Gantumur, Kenichiro Araki, Takehiko Yokobori, Takahiro Yamanaka, Tadashi Handa, Norifumi Harimoto, Akira Watanabe, Norio Kubo, Takamichi Igarashi, Mariko Tsukagoshi, Kouki Hoshino, Kei Hagiwara, Norihiro Ishii, Hiroshi Tanaka, Ryo Muranushi, Ken Shirabe
Publikováno v:
British Journal of Cancer
Background Intrahepatic cholangiocarcinoma (ICC) is a malignancy that is challenging to treat. Fibroblasts in ICC tissues have been identified as cancer-associated fibroblasts (CAFs) that promote the malignant behaviour of ICC cells. An antifibrotic
Autor:
Stefan Knop, Richard Greil, Karl Jochen Krenosz, Wolfram Poenisch, Hermann Einsele, Katja Weisel, Thomas Melchardt, Andreas L. Petzer, Martin Schreder, Roman Hájek, Dietger Niederwieser, Niklas Zojer, Wolfgang Willenbacher, Daniel Lechner, Heinz Ludwig, Eberhard Gunsilius, Alexander Egle
Publikováno v:
British Journal of Cancer
Background Ixazomib-revlimid-dexamethason showed significant activity in relapsed/refractory multiple myeloma (RRMM). Here, we evaluate ixazomib in combination with thalidomide and dexamethasone for induction treatment followed by ixazomib maintenanc
Autor:
William I. Bensinger, Nizar J. Bahlis, Jatin P. Shah, Heather J. Sutherland, Sonia Ammu, Cristina Gasparetto, Michael Kauffman, Sumit Madan, Richard Leblanc, Muhamed Baljevic, Christopher P. Venner, Ohad S. Bentur, Suzanne Lentzsch, Darrell White, Sascha A. Tuchman, Rami Kotb, Noa Biran, Chris Zhiyi Zhang, Christine Chen, Michael Sebag, Sharon Shacham, Adriana C Rossi, Brea Lipe, Gary J. Schiller, Natalie S. Callander, Dane Van Domelen, Andrew DeCastro, Osnat Ben-Shahar, Tianjun Zhou
Publikováno v:
British Journal of Cancer
British journal of cancer, vol 126, iss 5
British journal of cancer, vol 126, iss 5
Background Proteasome inhibitors (PIs), including carfilzomib, potentiate the activity of selinexor, a novel, first-in-class, oral selective inhibitor of nuclear export (SINE) compound, in preclinical models of multiple myeloma (MM). Methods The safe
Autor:
Ganessan Kichenadasse, Ross A. McKinnon, Andrew Rowland, Michael J. Sorich, Jessica M. Logan, Ahmad Y. Abuhelwa, Ashley M. Hopkins, Sarah Badaoui, Christos S. Karapetis
Publikováno v:
Br J Cancer
Background: Proton pump inhibitors (PPIs) are commonly used concomitant to cancer treatment and they induce gut microbiota changes. It is increasingly apparent that gut dysbiosis can reduce the effectiveness of immune checkpoint inhibitors(ICI). Howe